Please assess the completion status of the following clinical trial:

Trial Title: Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with residual (uncontrolled) hypertension on lisinopril monotherapy, defined as 24-hour ambulatory diastolic BP \>85 mmHg.~Exclusion Criteria:~A subject meeting any of the following conditions will be excluded from the study:~* History of serious adverse effects with ACE inhibitor, Coreg, or valsartan~* Known or suspected causes of secondary hypertension (e.g., renovascular stenosis, primary hyperaldosteronism)~* Known ischemic heart disease requiring beta-blocker therapy (includes angina, prior transmural myocardial infarction, coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty or stenting within 6 months prior to study entry).~* Heart failure (NYHA Functional Class II-IV)~* Obstructive valvular heart disease or obstructive hypertrophic cardiomyopathy~* Presence of clinically significant ventricular or supraventricular arrhythmias (e.g. atrial fibrillation/flutter), pre-excitation syndrome, second or third degree AV block, other conduction defects necessitating the implantation of a permanent cardiac pacemaker, or sick sinus syndrome.~* Chronic kidney disease (serum creatinine \>2.5 within past 6 months)~* Uncontrolled diabetes mellitus (i.e., a fasting blood glucose \>200 mg/dL \[\>11.1 mmol/L\] or hemoglobin A1c \> 10%~* History of alcohol or other drug abuse within 6 months prior to enrollment~* Concomitant treatment or probable need for treatment with prohibited medications. NSAIDs, diabetes medications and other chronic meds are permitted if continued throughout study without dosage change.~* Any other medical condition which renders the subject unable to complete the study or which would interfere with optimal participation in the study or produce a significant risk to the subject~* Those with persistent systolic BP elevations above 179 mmHg will be discontinued from the study as will those with any significant adverse effect of medication.~* Positive pregnancy test or failure to practice adequate contraception in women of child-bearing potential~* Bronchospastic asthma requiring chronic steroid or inhaler therapy~* Any women with child-bearing potential

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- (A) ARB first, beta-blocker second (Type: ACTIVE_COMPARATOR): Valsartan 160 mg daily (one week) and valsartan 320 mg daily (3 weeks) followed by carvedilol CR 20 mg daily (one week) and carvedilol CR 40 mg daily (3 weeks)
- (B) Beta-blocker first, ARB second (Type: ACTIVE_COMPARATOR): carvedilol CR 20 mg daily (one week) and carvedilol CR 40 mg daily (3 weeks) followed by valsartan 160 mg daily (1 week) and valsartan 320 mg daily (3 weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).